Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Acute Necrotizing Myositis in Systemic Lupus Erythematous
Neuromuscular and Clinical Neurophysiology (EMG)
P16 - Poster Session 16 (5:30 PM-6:30 PM)
1-010
*

Necrotizing autoimmune myopathies (NAM) are typically a subacute course with symmetric and proximal weakness described in the upper and lower extremities.   CKs are often elevated in the thousands and two antibodies are isolated in seropositive cases: Anti-HMGCR and anti-SRP.  Systemic Lupus Erythematous (SLE) has been previously associated with overlap syndrome but has only been described in a single case report of necrotizing myopathy though antibody status was not confirmed.   We present the case of a 21-year-old woman with nascent SLE with severe and acute nephritis and myocarditis who developed a proximal necrotizing myopathy.

Case Report

21-year-old woman with no past medical history was admitted to the hospital with acute gastritis.  Over a several week period, she developed nephritis requiring frequent dialysis, myocarditis and cerebritis necessitating aggressive immunotherapy including rituximab, hydroxychloroquine, cyclophosphamide and methylprednisolone.  Serology revealed elevated anti-double stranded DNA antibodies and other autoimmune markers meeting criteria for SLE.  On her 26th day of admission, she developed weakness in all extremities and mild pain/tenderness in her shoulders/calves.  Exam was notable for symmetric, proximal upper and lower extremity weakness with preserved sensation and reduced reflexes globally.  CKs were first noted as normal on admission but were seen as high as 3042 after weakness began.  MRI of the femur revealed inflammatory changes.  Quadriceps muscle biopsy demonstrated florid myophagocytosis with absence of inflammatory cells and connective tissue invasion.  There were no biopsy findings to support a hydroxychloroquine myopathy.  Antibody testing demonstrated a negative myositis panel and anti-SRP antibodies.  Her anti-HMGCR is pending.  Her weakness improved and CKs normalized within seven days of treatment with IVIG and steroids. 

This case represents a rare, biopsy proven NAM induced by SLE without meeting criteria for overlap myositis. These findings suggest that SLE be considered as a possible etiology for NAM cases. 

Authors/Disclosures
Jonathan Cauchi, MD (University of New Mexico Hospital)
PRESENTER
Dr. Cauchi has nothing to disclose.
No disclosure on file
Tahseen Mozaffar, MD, FÂé¶¹´«Ã½Ó³»­ (University of California Irvine) Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astellas Gene Therapy. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from Sanofi. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Astellas Gene Therpay. The institution of Dr. Mozaffar has received research support from Cartesian. The institution of Dr. Mozaffar has received research support from Cabaletta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH.